Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Buy CRO Tandem Labs

NEW YORK (GenomeWeb News) – Laboratory Corporation of America will buy the pharmaceutical and biotechnology contract research services company Tandem Labs for an undisclosed sum, LabCorp said today.
 
Under the agreement, Burlington, NC-based LabCorp will buy all of the outstanding shares of Tandem Labs and its parent company, Northwest Toxicology. Tandem will retain its name and management structure and will operate as part of LabCorp’s Esoterix clinical trials group.
 
Tandem offers discovery, preclinical, and clinical drug development services and has around 54,000 square feet of lab space and over 30 LC/MS/MS instruments spread among its branches in Utah, New Jersey, and Massachusetts.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.